文献速递肝肾功能剂量调整治疗药物监测与药物基因组学特殊人群用药

苗族痛风/高尿酸血症成人中奥昔嘌醇的群体药动学、药效学与药物遗传学建模

Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.
PubMed 文献 · Br J Clin Pharmacol · 2023-06-04

本研究在34例苗族受试者中开展别嘌醇滴定试验,采用非线性混合效应模型进行序贯群体PKPD分析,量化奥昔嘌醇清除率与黄嘌呤脱氢酶抑制的药遗传学变异,并基于最终模型模拟别嘌醇维持剂量以达标血清尿酸。

要点

  • SLC22A12 rs505802基因型与奥昔嘌醇清除率相关
  • PDZK1 rs12129861基因型影响奥昔嘌醇抑制黄嘌呤脱氢酶的效力
  • 基于去脂体重、肾功能及上述基因型的个体化别嘌醇剂量指南可预测达标情况

核心结论

  • 基于去脂体重、估算肌酐清除率及SLC22A12 rs505802、PDZK1 rs12129861基因型的别嘌醇剂量指南可个体化预测血清尿酸达标情况。

研究设计与样本

  • 苗族痛风/高尿酸血症成人受试者共34例,先接受别嘌醇100 mg每日两次共7天,随后150 mg每日两次共7天。
  • 采用非线性混合效应模型进行序贯群体药动学-药效学(PKPD)分析,并基于最终模型模拟达标所需的别嘌醇维持剂量。

主要发现

  • 奥昔嘌醇浓度-时间数据最佳拟合为一级吸收和消除的一室模型。
  • 奥昔嘌醇对血清尿酸的抑制用稳态奥昔嘌醇浓度的直接抑制型Emax模型描述。
  • 去脂体重、估算肌酐清除率和SLC22A12 rs505802基因型(每T等位基因0.32,95%CI 0.13,0.55)可预测奥昔嘌醇清除率差异。
  • 抑制50%黄嘌呤脱氢酶活性所需的奥昔嘌醇浓度受PDZK1 rs12129861基因型影响(每A等位基因-0.27,95%CI -0.38,-0.13)。
  • 同时携带PDZK1 rs12129861 AA和SLC22A12 rs505802 CC基因型的多数个体,无论肾功能和体重如何,使用低于最大剂量的别嘌醇即可达标(成功率至少75%)。

关键数值与推荐

  • SLC22A12 rs505802每T等位基因对奥昔嘌醇清除率的效应为0.32(95%CI 0.13,0.55)。
  • PDZK1 rs12129861每A等位基因对奥昔嘌醇抑制50%黄嘌呤脱氢酶活性所需浓度的效应为-0.27(95%CI -0.38,-0.13)。
  • PDZK1 rs12129861 AA且SLC22A12 rs505802 CC基因型者,别嘌醇低于最大剂量达标成功率至少75%。
  • PDZK1 rs12129861 GG且SLC22A12 rs505802 TT基因型者需超过最大剂量别嘌醇。

临床怎么用

  • 临床可依据去脂体重、估算肌酐清除率及SLC22A12 rs505802、PDZK1 rs12129861基因型个体化选择别嘌醇起始与维持剂量。
  • 对PDZK1 rs12129861 GG且SLC22A12 rs505802 TT基因型患者,应考虑换用替代降尿酸药物而非超最大剂量别嘌醇。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to quantify identifiable sources of variability, including key pharmacogenetic variants in oxypurinol pharmacokinetics and their pharmacodynamic effect on serum urate (SU). METHODS: Hmong participants (n = 34) received 100 mg allopurinol twice daily for 7 days followed by 150 mg allopurinol twice daily for 7 days. A sequential population pharmacokinetic pharmacodynamics (PKPD) analysis with non-linear mixed effects modelling was performed. Allopurinol maintenance dose to achieve target SU was simulated based on the final PKPD model. RESULTS: A one-compartment model with first-order absorption and elimination best described the oxypurinol concentration-time data. Inhibition of SU by oxypurinol was described with a direct inhibitory Emax model using steady-state oxypurinol concentrations. Fat-free body mass, estimated creatinine clearance and SLC22A12 rs505802 genotype (0.32 per T allele, 95% CI 0.13, 0.55) were found to predict differences in oxypurinol clearance. Oxypurinol concentration required to inhibit 50% of xanthine dehydrogenase activity was affected by PDZK1 rs12129861 genotype (-0.27 per A allele, 95% CI -0.38, -0.13). Most individuals with both PDZK1 rs12129861 AA and SLC22A12 rs505802 CC genotypes achieve target SU (with at least 75% success rate) with allopurinol below the maximum dose, regardless of renal function and body mass. In contrast, individuals with both PDZK1 rs12129861 GG and SLC22A12 rs505802 TT genotypes would require more than the maximum dose, thus requiring selection of alternative medications. CONCLUSIONS: The proposed allopurinol dosing guide uses individuals' fat-free mass, renal function and SLC22A12 rs505802 and PDZK1 rs12129861 genotypes to achieve target SU.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wen YF, Brundage RC, Roman YM, et al. Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia. Br J Clin Pharmacol. 2023. PMID: 37202871. doi:10.1111/bcp.15792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。